Fortress Biotech (FBIO) Q2 FY26 earnings call

Commercial execution in the dermatology subsidiary drove positive operational leverage as accelerating lead-brand adoption widened gross-to-net realization. Continued payer formulary wins and expanded field-force coverage underpin management's expectation for sustained positive core earnings through the remainder of the fiscal year.